Exploring Targets for Heart Failure Using Mendelian Randomization, Colocalization, Summary Data-based Mendelian...

Area of Science:

• Cardiovascular Genetics
• Pharmacogenomics
• Systems Biology

Background:

• Heart failure (HF) is a widespread cardiovascular condition with a substantial impact on quality of life.
• Current HF treatments face limitations, highlighting the need for novel therapeutic strategies.
• Identifying causal genetic factors is crucial for advancing HF management.

Purpose of the Study:

• To investigate the causal relationships between druggable genes and heart failure (HF) using Mendelian randomization (MR).
• To identify novel genetic targets for HF treatment.
• To explore potential drug candidates for these targets.

Main Methods:

• Mendelian randomization (MR) analysis to assess gene-HF causality.
• Colocalization and summary data-based Mendelian randomization (SMR) for validation.
• Gene Ontology (GO), KEGG enrichment, and protein-protein interaction (PPI) network analysis.
• Drug prediction and molecular docking for target-drug identification.

Main Results:

• Eight potential therapeutic targets for HF were identified: 4 risk factors (CYP11A1, GALT, KCNH2, METRN) and 4 protective factors (APOM, CHD4, IL11RA, LPAR5).
• These genes are implicated in metabolic regulation and cardiac electrophysiological processes.
• Potential drugs like mitotane were identified, with PCR confirming mitotane's association with CYP11A1 and KCNH2.

Conclusions:

• Novel druggable genetic targets for heart failure have been identified.
• These targets, involved in metabolism and electrophysiology, present opportunities for drug development.
• Targeted therapies may improve treatment efficacy and clinical outcomes for HF patients.